Recurrence Rate of Hemorrhoidal Disease at 10 Years and More After HAL Doppler or HAL-RAR Intervention
Launched by UNIVERSITY HOSPITAL, GRENOBLE · Jan 28, 2021
Trial Information
Current as of June 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the long-term results of a specific treatment for hemorrhoidal disease called HAL-RAR, which combines two methods to address both the blood supply and the support structures of the affected area. Researchers want to find out how many patients experience a return of their hemorrhoids ten years or more after receiving this treatment. The goal is to gather valuable information to help improve future care for individuals with this condition.
To participate in the study, you must be at least 18 years old and have undergone treatment for hemorrhoidal disease at least ten years ago. The trial is open to all genders. If you decide to join, you can expect to share your experiences and possibly undergo some follow-up assessments related to your previous treatment. It’s important to note that individuals who are not comfortable participating or are under 18 years old will not be eligible for this study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient operated for hemorrhoidal disease for 10 or more
- • Age 18 and over
- • Informed patients
- Exclusion Criteria:
- • Patient opposition
- • Minor patient
About University Hospital, Grenoble
The University Hospital of Grenoble is a leading academic medical center dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent sponsor of clinical trials, the hospital leverages its expertise in various medical disciplines to facilitate cutting-edge studies that aim to improve treatment outcomes and enhance patient safety. With a strong commitment to collaboration, the University Hospital of Grenoble engages in partnerships with academic institutions, industry leaders, and regulatory bodies to drive scientific discovery and translate research findings into clinical practice. Its state-of-the-art facilities and multidisciplinary teams ensure rigorous adherence to ethical standards and regulatory guidelines, fostering an environment where groundbreaking research can thrive.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Grenoble, , France
Patients applied
Trial Officials
Giorgia Mastronicola
Principal Investigator
CHU Grenoble Alpes
Jean Luc FAUCHERON, MD-PhD
Study Director
CHU Grenoble Alpes
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials